These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 8810612)
21. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
22. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
23. Assessment of serum CYFRA 21-1 in lung cancer. Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502 [TBL] [Abstract][Full Text] [Related]
24. [CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors]. Hoefliger M; Morant R; Riesen W; Baumgartner G; Engler H Schweiz Med Wochenschr; 1994 Nov; 124(44):1966-70. PubMed ID: 7973529 [TBL] [Abstract][Full Text] [Related]
25. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
26. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607 [TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. Pujol JL; Cooper EH; Grenier J; Purves DA; Lehmann M; Ray P; Aouta MD; Bashir M; Godard P; Michel FB Eur J Cancer; 1994; 30A(12):1768-74. PubMed ID: 7880603 [TBL] [Abstract][Full Text] [Related]
28. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
29. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Pujol JL; Boher JM; Grenier J; Quantin X Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G Lung; 2001; 179(1):57-65. PubMed ID: 11479694 [TBL] [Abstract][Full Text] [Related]
33. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168 [TBL] [Abstract][Full Text] [Related]
34. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Rastel D; Ramaioli A; Cornillie F; Thirion B Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651 [TBL] [Abstract][Full Text] [Related]
35. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
36. [Level of cytokeratin-19 in serum of patients with non small cell lung cancer]. Cynowska B; Słomiński JM; Wyrwiński J Pneumonol Alergol Pol; 1995; 63(11-12):615-20. PubMed ID: 8616476 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546 [TBL] [Abstract][Full Text] [Related]
39. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546 [TBL] [Abstract][Full Text] [Related]
40. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients. Quillien V; Ramee MP; Bansard JY; Meritte H; Briens E; Logeais Y; Langanay T; Corbineau H; Dazord L Anticancer Res; 1995; 15(6B):2857-63. PubMed ID: 8669879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]